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Routine data collection efforts are a necessary, often underappreci-
ated, component of nearly all cancer research and prevention ef-
forts. Public health cancer surveillance data are crucial for identi-
fying needs, planning interventions, directing public health re-
sources,  and evaluating the overall  effectiveness of  initiatives
aimed at preventing or treating cancer and its negative health con-
sequences. As the nation’s health protection agency, the Centers
for Disease Control and Prevention (CDC) provides resources for
disease surveillance systems to help protect our nation against ex-
pensive and dangerous health threats, including cancer. Therefore,
public health surveillance is a core function of CDC. In this art-
icle we briefly describe CDC’s approach to cancer surveillance in
our public health programs and other federal initiatives to monitor
cancer-related outcomes. We also describe our premier cancer in-
cidence surveillance system, the National Program of Cancer Re-
gistries, and discuss uses and applications of the program’s critic-
al cancer data.
CDC’s Public Health Surveillance of
Cancer
Cancer is the second leading cause of death in the United States
(1) and therefore a focus of public health efforts. One defining fea-
ture of the public health approach to cancer control is its reliance
on population data for planning and evaluating efforts aimed at
preventing the health consequences of cancer. The public health
cancer prevention continuum (2,3) includes primary prevention
such as tobacco control, human papilloma virus (HPV) vaccina-
tion, and removal of precancerous polyps during screening colono-
scopies to prevent progression to colorectal cancer; secondary pre-
vention (early detection) such as screening mammography and
low-dose computed tomography among current or former heavy
smokers to identify early-stage lung cancer; and tertiary preven-
tion, which involves cancer survivorship care to reduce disability,
other health outcomes associated with a cancer diagnosis or its
treatment, and cancer recurrence and progression. Because of the
heterogeneity of cancer, this prevention continuum differs across
cancer types, as do the unique risk factors, associated disorders,
and intervention strategies.
The World Health Organization defines public health surveillance
as the continuous, systematic collection, analysis, and interpreta-
tion of health-related data needed for the planning, implementa-
tion, and evaluation of public health practice (4). This compre-
hensive definition of surveillance along with the heterogeneity of
the disease and its complex public health prevention continuum
means cancer surveillance is an exceptionally broad concept. It in-
cludes measurement of risk factors; assessment of use of health
services such as vaccination rates and screening; and cancer pre-
valence, incidence, mortality, and survival rates and various out-
comes affecting cancer survivors.
Conducting public health surveillance is one of CDC’s core func-
tions, yet no comprehensive review of the agency’s heterogen-
eous public health cancer surveillance activities has been conduc-
ted. This article summarizes the key components of CDC’s cancer
surveillance approach with a special emphasis on cancer incid-
ence data collected through our National Program of Cancer Re-
gistries (NPCR). CDC compiles extensive data with direct and in-
direct implications for cancer, either collected directly or in collab-
oration with funded or unfunded partners. We focus on surveil-
lance data used by CDC programs for planning, implementation,
and evaluation of public health practice.
CDC’s Approach to Cancer Surveillance
Surveillance of cancer risk factors
CDC’s  Division  of  Cancer  Prevention  and  Control  (DCPC)
provides resources and technical expertise for cancer-related ques-
tions included in the Behavioral Risk Factor Surveillance System
(BRFSS) (5). Questions are included in BRFSS on a routine, rotat-
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ing basis related to breast cancer screening (mammography), cer-
vical  cancer  screening  (Papanicolaou  test  and  HPV test),  and
colorectal  cancer  screening (home blood stool  test,  sigmoido-
scopy, or colonoscopy). Cancer screening questions are included
in BRFSS every 2 years in the core survey, which yields state-by-
state prevalence and trends in cancer screening in accordance with
the US Preventive Services Task Force (USPSTF) recommenda-
tions (6).  DCPC also sponsors optional  modules in support  of
CDC cancer program priorities, including questions on excess sun
exposure (BRFSS 2010, 2012, and 2016 surveys), HPV testing
and vaccination (BRFSS 2013 and 2014 surveys), shared decision
making about prostate-specific antigen (PSA) tests (BRFSS 2012,
2013,  2015,  and  2016  surveys),  clinical  breast  examination
(BRFSS 2015 and 2016 surveys), and cancer survivorship (BRFSS
2009, 2010, 2012, 2014, and 2016 surveys). Cancer survivorship
questions include self-reported cancer diagnoses and basic treat-
ment information, source of health care, health insurance issues,
clinical trial participation, and other outcomes such as pain. The
BRFSS core survey and other optional modules yield data on can-
cer risk factors such as smoking, obesity, and physical inactivity.
BRFSS  also  collects  information  about  comorbid  conditions,
which is critical given the large overlap between cancer and other
chronic diseases (7). Information about which states administered
which optional modules across years is available on the BRFSS
website (www.cdc.gov/brfss/questionnaires/index.htm).
DCPC collaborates with the National Center for Health Statistics
(NCHS) and the National Cancer Institute (NCI) to support ques-
tions and special supplements on the National Health Interview
Survey (NHIS). The core cancer questions provide data on self-re-
ported cancer prevalence, various cancer-associated health behavi-
ors, and access to and use of cancer-related health. DCPC and NCI
support the NHIS Cancer Control Supplement, which periodically
presents a focused examination of issues pertaining to cancer-re-
lated behaviors, screening, and risk assessment. The cancer-re-
lated  questions  vary  across  years  to  reflect  emerging  needs.
DCPC-sponsored NHIS questions have been asked in 2000, 2003,
2005, 2008, 2010, 2013, and 2015. More information about NHIS
supplements is  available on the NHIS website  (www.cdc.gov/
nchs/nhis/supplements_cosponsors.htm).
Other CDC data sources that routinely contribute to cancer sur-
veillance and research include the National Health and Nutrition
Examination Survey (www.cdc.gov/nchs/nhanes/index.htm), the
Youth  Risk  Behavior  Surveillance  System  (www.cdc.gov/
healthyyouth/data/yrbs/index.htm), the Medical Expenditure Pan-
el Survey (https://meps.ahrq.gov/mepsweb/), and program-specif-
ic clinical data collection initiatives supported through the Nation-
al  Breast  and  Cervical  Cancer  Early  Detection  Program
(NBCCEDP) (8) and the Colorectal Cancer Control Program (9).
Surveillance of cancer incidence and mortality
DCPC collects  data  on new cancer  cases  diagnosed each year
through NPCR covering 96% of the United States (Figure) (10).
When combined with data collected through NCI’s Surveillance,
Epidemiology and End Results (SEER) program (11), these can-
cer  data  yield  incidence  information  for  100% of  the  United
States. These data collection efforts also provide estimates of can-
cer survival  and prevalence.  Cancer mortality data come from
NCHS’s National Vital Statistics System (NVSS), which is the
oldest and most comprehensive public health surveillance effort in
the United States (12). Combining cancer incidence and mortality
data provides CDC with one of the most sophisticated and com-
plete public health surveillance systems in the nation.
Figure. Centers for Disease Control and Prevention’s (CDC’s) National Program
of Cancer Registries (NPCR) 2017 funding,  showing which states receive
funding from CDC’s NPCR and which do not.
 
National Program of Cancer Registries
(NPCR)
CDC’s cancer incidence data come from NPCR, which was estab-
lished by Congress in 1992.  From 2012 through 2017,  CDC’s
NPCR funded central cancer registries in 45 states, the District of
Columbia, Puerto Rico, and the US Pacific Island jurisdictions.
Central cancer registries are responsible for collecting, processing,
and analyzing complex data from medical facilities on every in
situ  and invasive cancer  (with  the  exception of  basal  cell  and
squamous cell carcinoma of the skin) diagnosed among residents
in their geographic catchment area (eg, state). Consequently, data
in the state or territorial central registries represent everyone dia-
gnosed or treated for cancer. A brief summary of the data items
collected  by  all  central  cancer  registries  is  shown in  Table  1.
NPCR data collection occurs through medical record abstraction
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or electronic reporting at the health care facility level. Incident
cases from all hospitals, physicians’ offices, pathology laborator-
ies, treatment facilities, and other medical facilities are reportable
to the central cancer registry.
The central cancer registry also links data with state and national
databases to supplement and improve the quality of data. Every
central cancer registry routinely links cancer data with that of its
state death files, NBCCEDP, the National Death Index, and the In-
dian Health Service. Some registries optionally link with other
data sources, such as Medicare and Medicaid claims files to ad-
dress gaps identified in their data or improve the usefulness of the
data for local cancer control activities. Because the data in a single
record come from various sources, the central registry is respons-
ible for consolidating the information into a single record on each
cancer case and submitting a subset of its data to CDC annually,
including any updates from previous years.
To ease the burden of  such a  complex data  collection system,
CDC has several surveillance informatics initiatives to automate
processes and use electronic data exchange in cancer reporting.
Examples include cancer reporting from ambulatory providers to
registries for Stage 2 Meaningful Use and the development of a
natural language processing web-based repository to facilitate ana-
lytic data extraction from text-based records (13,14).
NPCR uses North American Association of Central Cancer Regis-
tries uniform data standards (15) and works with NCI to ensure
compatibility and comparability of cancer incidence and to pub-
lish annual data in the US Cancer Statistics Incidence and Mortal-
ity Web-based Report (16). Although this online report hosts the
official US federal cancer statistics, NPCR and SEER data are also
available through other online tools, including CDC-WONDER
(https://wonder.cdc.gov/), CDC’s Environmental Public Health
Tracking Network (www.cdc.gov/nceh/tracking/), and State Can-
cer Profiles (https://statecancerprofiles.cancer.gov/). NPCR analyt-
ic data sets are also available to researchers interested in using
these  data  (https://www.cdc.gov/cancer/npcr/public-use/).
Through careful coordination and collaborations with our cancer
surveillance partners, NPCR data are comparable with those of
other countries and are included in the Cancer Incidence in Five
Continents (http://ci5.iarc.fr/Default.aspx) series providing in-
formation on the global burden of cancer.
Application of Cancer Surveillance Data
for Program Monitoring, Evaluation, and
Research
Incidence data from NPCR and SEER and cancer mortality data
from NCHS NVSS are the basis for nearly all cited cancer statist-
ics and projections, including the Annual Report to the Nation on
the Status of Cancer (17) and the American Cancer Society’s Can-
cer Facts and Figures (18). These surveillance activities, along
with data collected through BRFSS, NHIS, and other initiatives,
are vital to all cancer prevention programs.
National Comprehensive Cancer Control Program
Established in 1998, the National Comprehensive Cancer Control
Program (NCCCP) supports strategic approaches to preventing or
minimizing the impact of cancer in communities (19). CDC fun-
ded comprehensive cancer control initiatives in all 50 states, the
District of Columbia, 7 tribal groups, and 7 US Associated Pacific
Islands and Territories from 2012 through 2017 to build and sup-
port coalitions of stakeholders, use data to define and monitor the
cancer burden in their area, prioritize proven strategies for cancer
control, develop cancer plans, and put cancer plans into action.
NCCCP grantees develop state or local cancer plans based on the
burden of disease defined through NPCR, SEER, and NVSS can-
cer incidence and mortality data. NCCCP grantees also use these
data along with BRFSS risk factor, screening, and other cancer-re-
lated measures to evaluate and monitor cancer programs in their
geographic regions. For example, cancer registry data have been
used to show that Native Americans living in the Cherokee Na-
tion have higher colorectal cancer death rates than do other Native
Americans living in Oklahoma and across the United States. This
information has been used by the Cherokee Nation Comprehens-
ive Cancer Control Program to engage the Prevent Cancer Found-
ation to educate and empower Cherokee Nation citizens in pre-
venting and controlling colorectal cancer (20).
National Breast and Cervical Cancer Early Detection
Program
The NBCCEDP is a nationwide, comprehensive public health pro-
gram that provides uninsured and underserved women access to
timely breast and cervical cancer screening and diagnostic ser-
vices (8).  The NBCCEDP is implemented through cooperative
agreements  between  CDC  and  all  50  states,  the  District  of
Columbia, 5 US territories, and 11 American Indian/Alaska Nat-
ive tribes or tribal organizations and has been implemented from
2012 through 2017. In addition to providing direct services to wo-
men, grantees are required to collect and report a set of standard-
ized data elements for monitoring client demographics and clinic-
al outcomes of women screened through the NBCCEDP. These
data are also used to establish program policies and practices, as-
sess the national program’s screening outcomes, and respond to
information needs of CDC stakeholders and partners. NBCCEDP
data are routinely linked by grantees to cancer registries to con-
firm diagnosis and cancer prognostic factors and to allow compar-
isons of cancer incidence in program and nonprogram populations.
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A recent analysis (2015) used these data to compare characterist-
ics and cancer stage distribution of women enrolled with women
not enrolled in NBCCEDP (21). Findings from that analysis sug-
gest that the program has been effective in achieving its goal of
enrolling racial and ethnic minority populations.
Colorectal Cancer Control Program
CDC’s Colorectal Cancer Control Program (CRCCP) helps states
and tribes  across  the  United  States  increase  colorectal  cancer
screening rates among men and women aged 50 to 75 years (9).
The program focuses on increasing screening by implementing
priority evidence-based interventions recommended by the Guide
to Community Preventive Services. This approach allows grantees
to implement targeted evidence-based interventions and support-
ing strategies on a feasible scale and collect program-level and pa-
tient-specific  clinical  data that  show the program’s impact.  In
2015, CRCCP supported 24 state health departments, 6 universit-
ies, and 1 American Indian tribe. Six grantees were also funded to
provide screening to uninsured and underinsured people; as in the
NBCCEDP, these 6 grantees also report standardized clinical data
for people screened.
Healthy People 2020 and other national objectives
Healthy  People  2020  (HP2020)  (www.healthypeople.gov/)
provides quantifiable national objectives for improving the health
of all Americans. For cancer, HP2020 aims to reduce the number
of new cancer cases and the illness, disability, and death caused by
cancer. The 27 cancer objectives support monitoring trends in in-
cidence, death, and survival and reflect the importance of promot-
ing evidence-based screening for cervical, colorectal, and breast
cancer by measuring the use of screening tests recommended by
the USPSTF. The cancer-related HP2020 objectives are measured
through various CDC-supported data systems (Table 2).
Research
Several projects have used central cancer registries to recruit parti-
cipants for research studies. Population-based cancer registries are
useful in identifying samples of participants who meet criteria for
certain cancers. For example, one study assessed health-related
quality of life and health behaviors among colorectal cancer sur-
vivors recruited through the California Cancer Registry demon-
strating that the cancer registry can be a valuable source for identi-
fying and recruiting study participants (22,23). Cancer registries
have also been used to conduct laboratory studies, such as a study
that used tissue from HPV-related cancers from 7 central cancer
registries. Researchers were able to assess the proportion of HPV-
related cancers attributable to different types of HPV and estimate
the potential impact of scaling up coverage of HPV vaccines (24).
Other uses of NPCR data have involved comparative effective-
ness research applications by enhancing data collection to address
targeted questions, including the clinical use and prognostic value
of specific biomarkers (25). This enhanced data collection has
leveraged NPCR as a resource to conduct health services research
and examine patterns and disparities in cancer care.
Future Directions
DCPC is committed to continuously improving the accuracy, effi-
ciency, and timeliness of all cancer surveillance efforts it directly
funds or supports. One way cancer registries are doing this is by
remaining on the cutting edge of health information technology by
facilitating more electronic reporting and automated data manage-
ment techniques.  Through work with the cancer registry com-
munity and other key partners, such as the Office of the National
Coordinator and the Centers for Medicare & Medicaid Services,
NPCR has made great progress in developing a robust capability
for electronic exchange of certain cancer data. However, there is
much work to do. Sustained local, state, and federal cancer re-
gistry commitments are needed to continue to develop new tools
and software for the development and acceptance of additional
electronic cancer records. Through these efforts, the cost-effect-
iveness and timeliness of cancer surveillance is expected to im-
prove in the long term as registry staff spend less time engaged in
visual review, coding, and data entry and more time in quality as-
surance to improve the quality, completeness, and timeliness of
the data. CDC’s NPCR will continue to build the necessary infra-
structure for electronic reporting so that these efficiencies can be
realized in the future. Cancer surveillance data are the core of can-
cer epidemiology and outcomes in clinical cancer research. CDC
is dedicated to remaining a diligent steward of population-based
cancer surveillance and maintaining complete capabilities in can-
cer incidence surveillance throughout the entire nation to support
state and local activities. We also remain steadfast in making all
CDC data useful and available to those who need them, particu-
larly for program planning and monitoring, resource allocation,
and state and federal accountability.
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Tables
Table 1. Summary of Data Items Collected by All Central Cancer Registries, United States
Data Type Examples














Treatment Type of first course of definitive treatment
Date of first course of definitive treatment
Follow-up/recurrence/death Date of last contact
Date of death
Underlying cause of death
Abbreviations: ICD-O-3, International Classification of Disease for Oncology, Third Edition.
a Centers for Disease Control and Prevention does not receive patient identification information.
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Table 2. Healthy People 2020 Objectives and Associated Data Sources Related to Cancer, United States
Objective Data Source
Reduce the overall cancer death rate NVSS-M
Reduce the lung cancer death rate NVSS-M
Reduce the female breast cancer death rate NVSS-M
Reduce the death rate from cancer of the uterine cervix NVSS-M
Reduce the colorectal cancer death rate NVSS-M
Reduce the oropharyngeal cancer death rate NVSS-M
Reduce the prostate cancer death rate NVSS-M
Reduce the melanoma cancer death rate NVSS-M
Reduce invasive colorectal cancer NPCR, SEER
Reduce invasive uterine cervical cancer NPCR, SEER
Reduce late-stage female breast cancer NPCR, SEER
Increase the number of central, population-based registries from the 50 states and the District of Columbia that capture
case information on at least 95%of the expected number of reportable cancers
NPCR, SEER
Increase the proportion of cancer survivors who are living 5 years or longer after diagnosis SEER
Increase the mental and physical health-related quality of life of cancer survivors (developmental objective) NHISa
Increase the proportion of women who receive a cervical cancer screening based on the most recent guidelines NHIS
Increase the proportion of adults who receive a colorectal cancer screening based on the most recent guidelines NHIS
Increase the proportion of women who receive a breast cancer screening based on the most recent guidelines NHIS
Increase the proportion of women who were counseled by their providers about mammograms NHIS
Increase the proportion of women who were counseled by their providers about Papanicolaou (Pap) tests NHIS
Increase the proportion of adults who were counseled by their providers about colorectal cancer screening
(developmental objective)
NHISa
Increase the proportion of men who have discussed the advantages and disadvantages of the prostate-specific antigen
(PSA) test to screening for prostate cancer with their health care provider
NHIS
Reduce the proportion of adolescents in grades 9 through 12 who report sunburn (developmental objective) YRBSSa
Reduce the proportion of adults aged 18 years or older who report sunburn NHIS
Reduce the proportion of adolescents in grades 9 through 12 who report using artificial sources of ultraviolet light for
tanning
YRBSS
Reduce the proportion of adults aged 18 or older who report using artificial sources of ultraviolet light for tanning NHIS
Increase the proportion of adolescents in grades 9 through 12 who follow protective measures that may reduce the risk
of skin cancer
YRBSS
Increase the proportion of adults aged 18 years and older who follow protective measures that may reduce the risk of
skin cancer
NHIS
Abbreviations: NHIS, National Health Interview Survey; NPCR, National Program of Cancer Registries; NVSS-M, National Vital Statistics System-Mortality; SEER, Sur-
veillance, Epidemiology and End Results; YRBSS, Youth Risk Behavior Surveillance System.
a Potential data source for a developmental objective. Data sources were available for baseline but may not be available for monitoring changes.
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